Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Volpara Health Technologies.
RELATED STOCKHEAD STORIES
News
Market Highlights and 5 ASX Small Caps to watch on Friday
Health & Biotech
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
Volpara cracks its biggest deal yet with US$2.15m partnership
Health & Biotech
ASX Health Stocks: Pharmaxis progresses to Phase 2 study on bone marrow cancer
Health & Biotech
ScoPo’s Powerplays: Market volatility creates both buying and selling opportunities in the Health sector
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech
Volpara gets on the fast track as a leading player in lung care with two strategic US partnerships
Health & Biotech
ScoPo’s Powerplays: Profit-taking on the cards for health stocks that have had good runs
Stockhead TV
90 Seconds With… Ralph Highnam, CEO, Volpara Health Technologies Limited
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
News
Closing Bell: ASX rebounds from yesterday’s fall, led by 2.6pc gain in tech
Health & Biotech
ScoPo’s Powerplays: Healthcare sector has bounced back as earnings season kicks off, expect to buy on the dips
Health & Biotech
ASX health stocks today: AdAlta (ASX:1AD) leads after successful Phase I study
News
Closing Bell: Market slips, but Materials up 1.23%
Health & Biotech
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery
Health & Biotech
ScoPo’s Powerplays: ‘Prepare for a big jump in July’ as tax-loss selling in healthcare continues
Health & Biotech
